Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi," Milan 20122, Italy.
Department of Otolaryngology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan 20122, Italy.
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):12797-12802. doi: 10.1073/pnas.1705364114. Epub 2017 Nov 13.
Follicular helper T cells (Ts) are a key component of adaptive immune responses as they help antibody production by B cells. Differentiation and function of T cells are controlled by the master gene , but it is largely unclear how this transcription repressor specifies the T program. Here we asked whether BCL6 controlled helper function through down-regulation of specific microRNAs (miRNAs). We first assessed miRNA expression in T cells and defined a T-specific miRNA signature. We report that hsa-miR-31-5p (miR-31) is down-regulated in T; we showed that BCL6 suppresses miR-31 expression by binding to its promoter; and we demonstrated that miR-31 inhibits the expression of molecules that control T-helper function, such as CD40L and SAP. These findings identify a BCL6-initiated inhibitory circuit that stabilizes the follicular helper T cell program at least in part through the control of miRNA transcription. Although BCL6 controls T activity in human and mouse, the role of miR-31 is restricted to human T cell differentiation, reflecting a species specificity of the miR-31 action. Our findings highlight miR-31 as a possible target to modulate human T cell dependent antibody responses in the settings of infection, vaccination, or immune dysregulation.
滤泡辅助 T 细胞(Ts)是适应性免疫反应的关键组成部分,因为它们帮助 B 细胞产生抗体。T 细胞的分化和功能受主基因控制,但转录抑制因子如何特异性指定 T 程序在很大程度上尚不清楚。在这里,我们询问 BCL6 是否通过下调特定的 microRNAs(miRNAs)来控制辅助功能。我们首先评估了 T 细胞中的 miRNA 表达,并定义了 T 细胞特异性 miRNA 特征。我们报告 hsa-miR-31-5p(miR-31)在 T 细胞中下调;我们表明 BCL6 通过结合其启动子来抑制 miR-31 的表达;并证明 miR-31 抑制控制 T 辅助功能的分子的表达,例如 CD40L 和 SAP。这些发现确定了 BCL6 启动的抑制性回路,该回路至少部分通过 miRNA 转录的控制来稳定滤泡辅助 T 细胞程序。尽管 BCL6 在人和小鼠中控制 T 细胞的活性,但 miR-31 的作用仅限于人类 T 细胞分化,反映了 miR-31 作用的种属特异性。我们的研究结果强调了 miR-31 作为一种可能的靶点,可在感染、疫苗接种或免疫失调的情况下调节人类 T 细胞依赖性抗体反应。